On February 9, the Trump Administration announced plans to tap White House Deputy Chief of Staff Jim Carroll to lead the Office of National Drug Control Policy (ONDCP). Carroll will serve as the office’s Acting Director while he awaits confirmation for the post in the U.S. Senate. If confirmed, Carroll would oversee the administration’s response to the nation’s ongoing epidemic of drug overdoses and deaths, largely driven by opioids.
As a specialized executive policy office, ONDCP is responsible for coordinating the development and implementation of U.S. drug control policies, and its director serves as chief advisor to the president on drug-related issues. In addition, the office supports the White House’s Commission on Combating Drug Addiction and the Opioid Crisis and has traditionally administered various grant programs, such as the High Intensity Drug Trafficking Areas Program (HIDTA) and Drug-Free Communities. President Trump has proposed in his Fiscal Year (FY) 2019 budget to transfer both the HIDTA and Drug-Free Communities programs to the jurisdictions of the U.S. Department of Justice (DOJ) and U.S. Department of Health and Human Services (HHS), respectively.
Prior to joining the White House, Carroll, an attorney, served as General Counsel at the Office of Management and Budget and held various positions at the Ford Motor Company.